Should all patients with metabolic syndrome be treated with statins?

Nicola Abate, Manisha Chandalia

Research output: Contribution to journalArticle

Abstract

The metabolic syndrome is a constellation of cardiovascular risk factors that include atherogenic dyslipidemia, elevated blood pressure, abdominal/truncal obesity, and glucose intolerance. Current National Cholesterol Education Program (NCEP) recommendations for specific treatment of the metabolic syndrome are centered on therapeutic lifestyle changes. A recent publication from the NCEP Adult Treatment Panel III suggests pharmacologic intervention for parameters of metabolic syndrome, including dyslipidemia, hypertension, and hyperglycemia, to prevent cardiovascular disease, based on risk category. This review looks at the clinical trial evidence to support the use of statins in metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)72-76
Number of pages5
JournalCurrent Diabetes Reports
Volume6
Issue number1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Cholesterol
Education
Glucose Intolerance
Abdominal Obesity
Hyperglycemia
Life Style
Cardiovascular Diseases
Therapeutics
Clinical Trials
Blood Pressure
Hypertension

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Should all patients with metabolic syndrome be treated with statins? / Abate, Nicola; Chandalia, Manisha.

In: Current Diabetes Reports, Vol. 6, No. 1, 02.2006, p. 72-76.

Research output: Contribution to journalArticle

Abate, Nicola ; Chandalia, Manisha. / Should all patients with metabolic syndrome be treated with statins?. In: Current Diabetes Reports. 2006 ; Vol. 6, No. 1. pp. 72-76.
@article{d0d6f8b91cf2498e8d3bf8bd130b52be,
title = "Should all patients with metabolic syndrome be treated with statins?",
abstract = "The metabolic syndrome is a constellation of cardiovascular risk factors that include atherogenic dyslipidemia, elevated blood pressure, abdominal/truncal obesity, and glucose intolerance. Current National Cholesterol Education Program (NCEP) recommendations for specific treatment of the metabolic syndrome are centered on therapeutic lifestyle changes. A recent publication from the NCEP Adult Treatment Panel III suggests pharmacologic intervention for parameters of metabolic syndrome, including dyslipidemia, hypertension, and hyperglycemia, to prevent cardiovascular disease, based on risk category. This review looks at the clinical trial evidence to support the use of statins in metabolic syndrome.",
author = "Nicola Abate and Manisha Chandalia",
year = "2006",
month = "2",
doi = "10.1007/s11892-006-0055-2",
language = "English (US)",
volume = "6",
pages = "72--76",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Should all patients with metabolic syndrome be treated with statins?

AU - Abate, Nicola

AU - Chandalia, Manisha

PY - 2006/2

Y1 - 2006/2

N2 - The metabolic syndrome is a constellation of cardiovascular risk factors that include atherogenic dyslipidemia, elevated blood pressure, abdominal/truncal obesity, and glucose intolerance. Current National Cholesterol Education Program (NCEP) recommendations for specific treatment of the metabolic syndrome are centered on therapeutic lifestyle changes. A recent publication from the NCEP Adult Treatment Panel III suggests pharmacologic intervention for parameters of metabolic syndrome, including dyslipidemia, hypertension, and hyperglycemia, to prevent cardiovascular disease, based on risk category. This review looks at the clinical trial evidence to support the use of statins in metabolic syndrome.

AB - The metabolic syndrome is a constellation of cardiovascular risk factors that include atherogenic dyslipidemia, elevated blood pressure, abdominal/truncal obesity, and glucose intolerance. Current National Cholesterol Education Program (NCEP) recommendations for specific treatment of the metabolic syndrome are centered on therapeutic lifestyle changes. A recent publication from the NCEP Adult Treatment Panel III suggests pharmacologic intervention for parameters of metabolic syndrome, including dyslipidemia, hypertension, and hyperglycemia, to prevent cardiovascular disease, based on risk category. This review looks at the clinical trial evidence to support the use of statins in metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=33645278997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645278997&partnerID=8YFLogxK

U2 - 10.1007/s11892-006-0055-2

DO - 10.1007/s11892-006-0055-2

M3 - Article

VL - 6

SP - 72

EP - 76

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 1

ER -